ARQL - ア―キュ―ル (ArQule Inc.) ア―キュ―ル

 ARQLのチャート


 ARQLの企業情報

symbol ARQL
会社名 ArQule Inc. (ア―キュ―ル)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アーキュール(ArQule Inc.)はがん治療薬の研究・開発を行う臨床段階におけるバイオテクノロジー企業である。同社は「アーキュールキナーゼ阻害プラットフォーム」等の技術を通じて薬品の設計・開発を行っている。同社の製品「ARQ 197」はc-Met受容体チロシンキナーゼ(c-Met)の経口投与阻害剤である。c-Metは癌細胞の増殖、腫瘍の拡散、新血管の形成、特定の薬物療法の抵抗性における複数の役割に基づくがんの治療の鍵である。同社は日本・アジアのその他国において、ヒト癌適応症向けのARQ 197の商権をKyowa Hakko Kirinに、米国、ヨーロッパ、南アメリカ及び世界中におけるその他国において、商権をKyowa Hakko Kirinにそれぞれ許諾した。平成23年8月、Kyowa Hakko Kirinは「tivantinib」と「erlotinib」の併用の第III相ATTENTION(「エルロチニブ」と「Tivantinib」のアジア併用試験に対する上皮成長因子受容体(EGFR)変異のない進行非小細胞肺癌(NSCLC)のための「Erlotinib」)試験の開始を発表した。   ア―キュ―ルは、米国のバイオ医薬品企業。癌の治療薬の研究、開発を手掛ける。独自のプラットフォ―ムを用いて、主要製品候補であるc-Met受容体型チロシンキナ―ゼ阻害剤のtivantinib(ARQ 197)の開発を行う。また肝臓癌や肝細胞癌の治療薬の前臨床実験を手掛ける。   ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751 and Derazantinib products. The company was founded in 1993 and is headquartered in Burlington, MA.
本社所在地 One Wall Street Burlington MA 01803 USA
代表者氏名 Patrick J. Zenner Patrick J. Zenner
代表者役職名 Independent Chairman of the Board
電話番号 +1 781-994-0300
設立年月日 34304
市場名 NASDAQ National Market System
ipoyear 1996年
従業員数
url www.arqule.com
nasdaq_url https://www.nasdaq.com/symbol/arql
adr_tso
EBITDA EBITDA(百万ドル) -12.19000
終値(lastsale) 4.08
時価総額(marketcap) 443973298.8
時価総額 時価総額(百万ドル) 452.67860
売上高 売上高(百万ドル) 17.84400
企業価値(EV) 企業価値(EV)(百万ドル) 421.20460
当期純利益 当期純利益(百万ドル) -15.80200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 ArQule Inc. revenues increased from $0K to $17.8M. Net loss decreased 91% to $1.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest income increase from $59K to $329K (income) Stock Based Compensation decrease of 12% to $552K (expense) R&D- Stock Based Compensation decrease of 9% to $185K (expense).

 ARQLのテクニカル分析


 ARQLのニュース

   The Week Ahead In Biotech: Avadel, Epizyme In Focus In A Quiet Week  2019/12/15 20:49:18 Benzinga
Biotech stocks were seen consolidating last week after advancing in the previous week. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) reached a 52-week high of 121.16 Monday, although it has come off this level since then. The week saw huge moves in reaction to presentations at the American Society of Hematology annual meeting. A few M&A announcements were made, including Merck & Co., Inc.'s (NYSE: MRK ) deal to buy ArQule, Inc. (NASDAQ: ARQL ) and Sanofi SA's (NASDAQ: SNY ) proposed purchase of Synthorx Inc (NASDAQ: THOR ). Correvio Pharma Corp (NASDAQ: CORV ) … Full story available on Benzinga.com
   The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win  2019/12/12 12:38:44 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 11) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aprea Therapeutics Inc (NASDAQ: APRE ) Aptose Biosciences Inc (NASDAQ: APTO ) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ) Arvinas Inc (NASDAQ: ARVN ) Audentes Therapeutics Inc (NASDAQ: BOLD ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BioNTech SE – ADR (NASDAQ: BNTX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) GlaxoSmithKline plc (NYSE: GSK ) Gossamer Bio Inc (NASDAQ: GOSS ) Immunomedics, Inc. (NASDAQ: IMMU ) Incyte Corporation (NASDAQ: INCY ) IVERIC bio Inc (NASDAQ: ISEE ) Kadmon Holdings Inc (NYSE: KDMN ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) Repro-Med Systems, Inc.
   The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint  2019/12/11 12:21:31 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 10) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL )(agreed to be bought by Arvinas Inc (NASDAQ: ARVN ) Audentes Therapeutics Inc (NASDAQ: BOLD ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Bristol-Myers Squibb Co (NYSE: BMY )(reacted to ASH presentation) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GlaxoSmithKline plc (NYSE: GSK ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Gossamer Bio Inc (NASDAQ: GOSS ) Immunomedics, Inc. (NASDAQ: IMMU ) Incyte Corporation (NASDAQ: INCY ) IVERIC bio Inc (NASDAQ: ISEE ) The Medicines Company (NASDAQ: MDCO ) Merck & Co.
   The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares  2019/12/10 12:56:02 Benzinga
The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aptose Biosciences Inc (NASDAQ: APTO ) (moved on ASH presentation) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ), which agreed to be bought by Merck & Co., Inc. (NYSE: MRK ) Arvinas Inc (NASDAQ: ARVN ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BioNTech SE – ADR (NASDAQ: BNTX ) BridgeBio Pharma Inc (NASDAQ: BBIO ) (appointed oncology scientist Eli Wallace as chief scientific officer for its oncology programs) Bristol-Myers Squibb Co (NYSE: BMY ) (reacted to ASH presentation) Constellation Pharmaceuticals Inc (NASDAQ: CNST ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Epizyme Inc (NASDAQ: EPZM ) (reacted to ASH presentation) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) (reacted to ASH presentation) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Globus Medical Inc (NYSE: GMED ) Immunomedics, Inc.
   PreMarket Prep Recap: Small Biotech Firms Looking Healthy, Street Fades Macy's Downgrade  2019/12/09 18:08:59 Benzinga Feeds
When a particular sector gets hot in this momentum driven market, if often gets hotter. And that's exactly what's happening in the biotech sector. Whether it was on positive drug news from the ASH Conference or a takeover, the issues in the biotech sector dominated the largest percentage gainer list and were discussed at the top of today's PreMarket Prep Show . Merger Mania Continuing with last's week trend of consolidation in the industry, two major players Merck (NYSE: MRK ) and Sanofi (NYSE: SNY ), made acquisitions to bolster their pipeline and augment future growth. One was telegraphed by the price action at the end of last week and the other was kept under wraps. The price action last week in Arqule Inc (NASDAQ: ARQL ) gave no indication that the company was going to be taken out for $20/share as it posted a modest 9-cent gain for the week. However, the huge gain in Synthorx Inc . (NASDAQ: THOR ) last week, … Full story available on Benzinga.com
   The Week Ahead In Biotech: Avadel, Epizyme In Focus In A Quiet Week  2019/12/15 20:49:18 Benzinga
Biotech stocks were seen consolidating last week after advancing in the previous week. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) reached a 52-week high of 121.16 Monday, although it has come off this level since then. The week saw huge moves in reaction to presentations at the American Society of Hematology annual meeting. A few M&A announcements were made, including Merck & Co., Inc.'s (NYSE: MRK ) deal to buy ArQule, Inc. (NASDAQ: ARQL ) and Sanofi SA's (NASDAQ: SNY ) proposed purchase of Synthorx Inc (NASDAQ: THOR ). Correvio Pharma Corp (NASDAQ: CORV ) … Full story available on Benzinga.com
   The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win  2019/12/12 12:38:44 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 11) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aprea Therapeutics Inc (NASDAQ: APRE ) Aptose Biosciences Inc (NASDAQ: APTO ) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ) Arvinas Inc (NASDAQ: ARVN ) Audentes Therapeutics Inc (NASDAQ: BOLD ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BioNTech SE – ADR (NASDAQ: BNTX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) GlaxoSmithKline plc (NYSE: GSK ) Gossamer Bio Inc (NASDAQ: GOSS ) Immunomedics, Inc. (NASDAQ: IMMU ) Incyte Corporation (NASDAQ: INCY ) IVERIC bio Inc (NASDAQ: ISEE ) Kadmon Holdings Inc (NYSE: KDMN ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) Repro-Med Systems, Inc.
   The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint  2019/12/11 12:21:31 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 10) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL )(agreed to be bought by Arvinas Inc (NASDAQ: ARVN ) Audentes Therapeutics Inc (NASDAQ: BOLD ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Bristol-Myers Squibb Co (NYSE: BMY )(reacted to ASH presentation) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GlaxoSmithKline plc (NYSE: GSK ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Gossamer Bio Inc (NASDAQ: GOSS ) Immunomedics, Inc. (NASDAQ: IMMU ) Incyte Corporation (NASDAQ: INCY ) IVERIC bio Inc (NASDAQ: ISEE ) The Medicines Company (NASDAQ: MDCO ) Merck & Co.
   The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares  2019/12/10 12:56:02 Benzinga
The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aptose Biosciences Inc (NASDAQ: APTO ) (moved on ASH presentation) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ), which agreed to be bought by Merck & Co., Inc. (NYSE: MRK ) Arvinas Inc (NASDAQ: ARVN ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BioNTech SE – ADR (NASDAQ: BNTX ) BridgeBio Pharma Inc (NASDAQ: BBIO ) (appointed oncology scientist Eli Wallace as chief scientific officer for its oncology programs) Bristol-Myers Squibb Co (NYSE: BMY ) (reacted to ASH presentation) Constellation Pharmaceuticals Inc (NASDAQ: CNST ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Epizyme Inc (NASDAQ: EPZM ) (reacted to ASH presentation) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) (reacted to ASH presentation) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Globus Medical Inc (NYSE: GMED ) Immunomedics, Inc.
   PreMarket Prep Recap: Small Biotech Firms Looking Healthy, Street Fades Macy's Downgrade  2019/12/09 18:08:59 Benzinga Feeds
When a particular sector gets hot in this momentum driven market, if often gets hotter. And that's exactly what's happening in the biotech sector. Whether it was on positive drug news from the ASH Conference or a takeover, the issues in the biotech sector dominated the largest percentage gainer list and were discussed at the top of today's PreMarket Prep Show . Merger Mania Continuing with last's week trend of consolidation in the industry, two major players Merck (NYSE: MRK ) and Sanofi (NYSE: SNY ), made acquisitions to bolster their pipeline and augment future growth. One was telegraphed by the price action at the end of last week and the other was kept under wraps. The price action last week in Arqule Inc (NASDAQ: ARQL ) gave no indication that the company was going to be taken out for $20/share as it posted a modest 9-cent gain for the week. However, the huge gain in Synthorx Inc . (NASDAQ: THOR ) last week, … Full story available on Benzinga.com
   ArQule: The Ides Of Ibrutinib  2019-04-18
There is a tide in the affairs of men, which taken at the flood leads to fortune. Omitted all the voyage of their life, Is bound in shallows and in miseries. On such a full sea are we now afloat; And we must take the current when it serves Or lose our ventures. &#x…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ア―キュ―ル ARQL ArQule Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)